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Polymorphisms associated with adalimumab and infliximab response in moderate-
to-severe plaque psoriasis 
Aims-. This study evaluated the influence of pharmacogenetics in psoriatic patients 
treated with adalimumab and/or infliximab. Materials and methods-. Prospective 
observational study evaluating the association of 124 polymorphisms with the response 
to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque 
psoriasis at 3 months (N=95) and 6 months of treatment (N=90). Significant SNPs for 
univariate analysis were subjected to multivariate analysis. Results/Conclusions-. Five 
SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL12B), 
rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, 
rs1061624 (TNFR1B) was associated with PASI75 at 6 months. Nevertheless, these 
biomarkers should be validated in large-scale studies before implementation in clinical 
practice. 
 
1. Introduction 
Psoriasis is a chronic and inflammatory disease that affects 2-3% of the world 
population [1,2]. Apart from affecting the skin, where it generates scaly erythematous 
papules and plaques [3], it may course with a wide range of comorbidities such as 
psoriatic arthritis, inflammatory bowel disease, cardiovascular and psychosocial 
conditions that impair quality of life [1,4,5]. Although the etiology of psoriasis remains 
unknown, family and twins studies have demonstrated that genetic factors play an 
important role in the onset and development of this disease [6–8]. In fact, the presence 
of the HLA-C*:06:02 allele [9,10] and polymorphisms in different genes such as tumor 
necrosis factor α (TNFα), interleukins 12, 17 and 23 (IL-17, IL-12, IL-23), are potential 
risk factors in psoriasis [11,12]. Approved biologic drugs that target TNF (adalimumab, 
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etanercept and infliximab) are currently used as first line biological treatment for 
moderate-to-severe psoriasis resistant to other systemic treatments [13]. 
 
Adalimumab and infliximab are both TNF blocking antibodies. While adalimumab is a 
fully human monoclonal antibody, infliximab is a chimeric mouse monoclonal antibody 
against TNFα [14,15]. TNFα blocking antibodies are safe and effective drugs for 
psoriasis [16–18]. Nevertheless, they are expensive and, although rarely, they might 
cause serious adverse effects [18,19]. Moreover, around 30% of the patients do not 
respond to these treatments [18,19]. Both molecules share structure and can bind and fix 
complement. Therefore they can lyse cells that express TNFα on their surface [20]. 
However, etanercept, a soluble form of p75 TNFα receptor, cannot accomplish that 
function [14,20]. Structural differences between etanercept and TNFα blocking 
antibodies may be the cause of the dissimilarities found in the efficacy of the TNFα 
blocking agents. Thus, the main objective of this paper is to identify pharmacogenetic 
biomarkers that could identify non-responder patients to TNFα blocking antibodies 
(adalimumab and infliximab).  
 
2. Material and methods  
2.1. Experimental design 
This study included 95 patients treated with monoclonal antibodies targeting TNFα 
from the Dermatology Unit of the Hospital Universitario de La Princesa in Madrid, 
Spain. When a patient was treated with both antibodies, only the first drug was 
considered. Inclusion criteria of this study were the following: Caucasian patients older 
than 18 years that were diagnosed for moderate-to-severe psoriasis according to the 
Spanish Academy of Dermatology and Venereology Psoriasis Working Group 
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consensus document criteria [21]. They received adalimumab or infliximab treatment 
according to the Summary of Product Characteristics. Psoriasis Area and Severity Index 
(PASI) was used as effectiveness criteria to evaluate TNFα blocking antibodies 
response at 3 and 6 months of treatment. Patients that reduced at least 75% over their 
baseline PASI (PASI75) were considered responders to TNFα blocking antibodies. All 
the subjects included in this study signed a written informed consent that allowed SNPs 
genotyping. The protocol and informed consent document fulfilled Spanish law on 
biomedical research and both were approved by the Ethics Committee for Clinical 
Research of Hospital Universitario de La Princesa.  
 
2.2. Sample processing and genotyping 
A sample of 3 ml peripheral blood was extracted from each patient. DNA extraction 
was performed using the MagNa Pure® System (Roche Applied Science, USA) and 
quantified with a NanoDrop® ND-1000 Spectrophotometer (Wilmington, USA). 
Samples were stored at -80 ºC in the Clinical Pharmacology Department of the Hospital 
Universitario de La Princesa. We selected 124 polymorphisms based on an extensive 
review of articles describing the association between polymorphisms and multiple 
inflammatory diseases related to psoriasis (rheumatoid arthritis, psoriatic arthritis, 
Crohn’s disease) and response to biological drugs [22]. A list of all evaluated SNPs is 
shown in Supplementary Table 1. Three IL-17 polymorphisms were evaluated using 
human TaqMan® SNP Genotyping Assays (StepOne, Applied Biosystems, USA) as 
described previously [23] while one hundred and twenty one SNPs were evaluated 
using the Illumina Veracode genotyping platform (Human Genotyping Unit-CeGen, 
Madrid, Spain) [24]. 
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2.3. Statistical analysis 
Linkage disequilibrium, Hardy-Weinberg equilibrium (HWE), allele and genotype 
frequencies and the association between the SNPs and adalimumab and infliximab 
response were performed using the SNPStats program (Catalan Institute of Oncology, 
Barcelona, Spain) [25]. Only the SNPs which allele frequencies were in HWE were 
included in the multivariate analysis [26]. Every SNP was tested to determine which 
logistic regression model had the best adjustment according to the type of inheritance 
(dominant, recessive, codominant or additive). The optimal model was selected using 
the lower p value and the lower Akaike Information Criterion (AIC) [24]. Results were 
expressed as the odds ratio (OR), the 95% confidence interval (CI), and the p value. 
SNPs with p<0.05 in the univariate analysis were included in a multivariate logistic 
regression model using the SPSS programme (IBM SPSS v19 Inc Chicago, IL, USA). 
Moreover, when several SNPs were in linkage disequilibrium and were significant in 
the univariate analysis, we analyzed the association between haplotype and response 
using SNPstats. Statistical significance was set at p ≤ 0.05. 
 
3. Results  
3.1.  Study population 
Sixty-eight patients were treated with adalimumab: 42 patients as the first biologic 
treatment option, 21 as the second therapeutic option and 5 as the third option. Thirty-
four patients were subjected to treatment with infliximab: 28 patients as the first 
biologic option, 5 as the second treatment and 1 as the third therapeutic option. When 
both treatments were administered to the same patient, only the first biologic drug of 
these two possible options was considered (N=95): 32 with infliximab and 63 with 
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adalimumab. Seven patients received adalimumab and infliximab: 3 were both 
responders to infliximab and adalimumab and 4 failed to respond to both. Sixty-seven 
patients achieved a PASI75 response at 3 months of treatment (70.5%: 64.7% with 
adalimumab and 73.5% with infliximab). There were no differences between responders 
and non-responders in the clinical and demographic variables analyzed (Table 1). 
Ninety patients completed adalimumab or infliximab treatment for 6 months and 72 of 
these patients achieved a PASI75 (80.0 %: 82.5% with adalimumab and 86.2% with 
infliximab). 
 
3.2.  Effectiveness 
 
There was no association between the response to treatment (PASI75 at 3 months) and 
the following clinical or demographic characteristics: therapeutic option (p=0.360), 
gender (p=0.880), weight (p=0.290), age of the first biologic agent (p=0.680), age of 
onset of psoriasis (p=0.670), type of psoriasis (p=0.660), or presence of psoriatic 
arthritis (p=0.730). 
 
From the 124 SNPs analyzed, only 9 were not in HWE: rs10494292 (LELP1; p=0.037), 
rs187238 (IL-18; p=0.042), rs3812888 (COG6; p=0.041), rs11126740 (CTNNA2; 
p=0.047), rs2787094 (ADAM33; p=0.022), rs658971 (SLC12A8; p=0.037), rs12191877 
(HLA-C; p=0.034), rs3027898 (IRAK1; p<0.001), rs3761548 (FOXP3; p<0.001). These 
SNPs were not included in the analysis.  
 
At 3 months of treatment, univariate analysis showed significant differences in PASI75 
for 19 SNPs (Table 2). However, when they were tested for multivariate analysis, 
significant results were only obtained for five polymorphisms: rs6661932 (IVL), 
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rs2546890 (IL12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 
(SLC9A8). Polymorphisms in the IVL, NFκB and SLC9A8 genes increased the risk of no 
response to adalimumab or infliximab whereas SNPs in the IL-12B and the ZNF816A 
genes reduced the risk of no response to these biologic drugs.  
 
There was no association of the response to treatment (PASI75 at 6 months) and the 
following clinical or demographic characteristics: therapeutic option (p=0.520), gender 
(p=0.830), weight (p=0.920), age of the first biologic agent (p=0.440), age of onset of 
psoriasis (p=0.210), type of psoriasis (p=0.093), or presence of psoriatic arthritis 
(p=0.690). 
 
Moreover, we analyzed the association of the 124 SNPs with the response at 6 months 
in the 90 patients that continued with the treatment of adalimumab or infliximab. Only 8 
SNPs were not in HWE: rs2485558 (RYR2; p=0.049), rs187238 (IL-18; p=0.019), 
rs10494292 (LELP1; p=0.035), rs3812888 (COG6; p=0.034), rs2787094 (ADAM33; 
p=0.020), rs658971 (SLC12A8; p=0.035), rs3027898 (IRAK1; p<0.001), rs3761548 
(FOXP3; p<0.001). These SNPs were not included in the analysis. 
 
At 6 months of treatment, univariate analysis showed significant differences in PASI75 
for 12 SNPs (Table 3). However, when we performed multivariate analysis only one 
SNP reduced the risk of no response to adalimumab or infliximab: rs1061624 
(TNFR1B). 
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4. Discussion  
 
Several pharmacogenetic studies have been performed to detect genetic biomarkers that 
could predict TNFα blocking antibodies in psoriasis (Table 4) [24,27–40]. Our study is 
the first to analyze the association of a high number of candidate SNPs (N=124) with 
TNFα blocking antibodies treatment in psoriasis patients. We have made a comparison 
of the previous publications that studied SNPs which could affect anti-TNF drug 
response (Table 4) [24,27–40]. However, only few of these publications have focused 
on the specific markers that could predict adalimumab and infliximab response. We 
have found 5 SNPs associated with TNFα blocking antibodies response. The SNPs are 
the following: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 
(ZNF816A) and rs645544 (SLC9A8), were associated with PASI75 at 3 months. 
Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months.  
 
IVL is a product of the PSORS4 locus, located on chromosome 1q21 in the epidermal 
differentiation complex region and widely associated with psoriasis susceptibility that 
encodes involucrin [41]. Involucrin is a protein involved in keratinocytes and epidermal 
differentiation that plays an important role in psoriasis [42]. rs6661932 (IVL) has been 
associated with early onset of psoriasis in a Chinese population [43]. However, it has 
not been previously associated with anti-TNF drug response. Our study shows that 
carriers of the T allele of rs6661932 (IVL) were less likely to respond to infliximab or 
adalimumab. 
 
IL-12B is a proinflammatory cytokine that induces T helper 1 (Th1) pathway. Previous 
publications have suggested that IL-12B plays an important role in psoriasis 
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development [12,44,45]. Furthermore, rs2546890 (IL-12B) is associated with the 
susceptibility to develop psoriasis [46] and to develop psoriatic arthritis in psoriasis 
patients [47]. Although the polymorphisms in IL-12B (rs6887695 and rs3212227) do 
not influence the response globally to anti-TNF drugs [28], we found that carriers of the 
A allele in rs2546890 are more likely to respond to adalimumab or infliximab. These 
results agree with a previous publication from our laboratory that demonstrated that 
carriers of the G allele in this polymorphisms were more likely not to respond globally 
to anti-TNF drugs [24]. 
 
Furthermore, NFKBIA encodes a member of the NF-κB inhibitor family; a negative 
inhibitor of the immune response that plays an important role in psoriasis [48]. 
rs2145623 (NFKBIA) was associated with psoriasis susceptibility in a previous 
publication [46]. We have shown that carriers of the G allele in this SNP are less likely 
to respond to infliximab or adalimumab. This SNP has previously been associated with 
ustekinumab (a different drug used to treat moderate-to-severe psoriasis) response [49]. 
Nevertheless, previous publications failed to find an association between rs2145623 
(NFKBIA) and etanercept response [50,51].  
 
ZNF816A gene encodes a zinc-finger transcription factor involved in different 
regulatory functions such as the recognition of RNA and proteins [52]. rs9304742 
(ZNF816A) has previously been associated with psoriasis susceptibility [8,53]. Our 
results showed that the presence of the C allele of this SNP is associated with a better 
response to TNFα blocking antibodies. However, a previous publication from our 
laboratory has demonstrated that carriers of the C allele for rs9304742 (ZNF816A) were 
less prone to respond globally to TNFα blockers (adalimumab, etanercept and 
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infliximab) [24]. Nevertheless, further studies with a higher number of patients should 
be done to confirm these results. Carriers of the C allele for rs9304742 (ZNF816A) were 
more likely to respond to ustekinumab in psoriasis patients [49].  
 
SLC9A8 encodes a sodium-hydrogen exchanger which is in the group of integral 
transmembrane proteins that exchange extracellular Na
+
 for intracellular H
+
 [54]. These 
channels have multiple functions, which include regulation of cell volume, intracellular 
pH homeostasis and electroneutral NaCl absorption in epithelia [54]. rs645544 
(SLC9A8) has been previously associated with psoriasis susceptibility [55]. 
Nevertheless, it has not been associated with anti-TNF drugs´ response so far. The 
present study shows that carriers of the G allele for the rs645544 SNP are less likely to 
respond to TNFα blocking antibodies.  
 
TNFR1B encodes the receptor of tumor necrosis factor. Polymorphisms in this gene 
have been previously associated with psoriasis susceptibility [56]. Our results show that 
carriers of the G allele in rs1061624 (TNFR1B) have more probability to respond to 
infliximab or adalimumab at 6 months. Although TNFR1B rs1061624 and rs3397 did 
not independently associate with infliximab efficacy, the AT haplotype (rs1061624A – 
rs3397 T) had a significant difference in distribution in responders and non-responders 
to infliximab in Crohn´s disease [56]. To our knowledge, no publications have analyzed 
the prediction value of the AT haplotype in adalimumab response. Moreover, the GT 
haplotype (rs2230926 T – rs610604 G) was associated with a good response to all 
TNFα blocking agents [37]. Two studies have shown that carriers of the G allele for the 
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rs1061622 (TNFR1B) SNP were more likely not to respond globally to anti-TNF drugs 
[32,57].  
 
Table 4 summarizes previous pharmacogenetic studies that searched for biomarkers 
which could predict anti-TNF drugs response in psoriasis. From the 21 SNPs that have 
been previously associated to anti-TNF drugs response, we have analyzed 10 in the 
present paper. We have only confirmed one of them [rs2546890 (IL12B)] in the 
multivariate analysis. However, five more SNPs [rs1801274 (FCGR2A), rs6311 
(HTR2A), rs96844 (MAP3K1), rs1061622 (TNFRSF1B) and rs2230926/rs610604 
(TNFAIP3)] were confirmed in the univariate analysis but not in the multivariate 
analysis. These discrepancies may be explained by the diverse SNPs and covariates 
included in the analysis. Our study analyzes simultaneously 124 SNPs while most of the 
pharmacogenetic studies focus on a maximum of 6 SNPs. Thus, these results may be 
influenced by the diverse number of SNPs and factors included in the multivariate 
analysis of the different publications. Besides, we have to consider that most of the 
previous studies have been performed in patients treated with any of the approved anti-
TNF agents (adalimumab, etanercept and infliximab) whereas this present publication 
focuses in the response to adalimumab or infliximab.  
 
A previous study showed that patients presenting the C allele in rs763780 (IL-17F) were 
more likely not to respond to infliximab [23]. However, no differences were observed 
between responders and non-responders to adalimumab and infliximab in the present 
publication. These results suggest that rs763780 (IL-17F) may be a specific marker of 
infliximab response. Furthermore, a previous publication showed that patients carrying 
the A allele in the rs11209026 (IL-23R) polymorphism were more likely not to respond 
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to a 6 months treatment with infliximab [28]. However, this result was not confirmed in 
the present study that analyzed simultaneously adalimumab and infliximab response. 
Therefore, these results suggest that rs11209026 (IL-23R) may be a specific biomarker 
of infliximab response at 6 months of treatment.  
 
In the present study we show that rs12191877 (HLA-C) is not associated with 
adalimumab response. This SNP has also been associated with psoriasis and is in 
linkage disequilibrium with HLA-C*0602 [58,59]. These results agree with those of a 
recent article published by Talamonti et al. 2017 [60]. They showed that the presence of 
the HLA-C:06:02 allele could not predict long –term adalimumab response in moderate-
to-severe Italian patients (n=122). Taken together, these two studies suggest that the 
presence of the HLA-C*0602 allele cannot predict short- term nor long-term response to 
adalimumab.  
 
The main limitation of this study is the small sample size. Nevertheless, this is an 
observational study that does not interfere with routine clinical practice so the study 
population was limited by the number of patients subjected to treatment with 
adalimumab or infliximab. This reduced sample size [adalimumab (N=68) and 
infliximab (N=34)] did not allow us to perform an individual analysis with any of these 
drugs. Nevertheless, the reduced sample size was compensated by an exhaustive follow-
up of patients and a deep analysis of their data. Few studies have evaluated the effect of 
polymorphisms on the response to TNFα blocking antibodies in moderate-to-severe 
psoriasis [24,27–33]. Consequently, our findings are an addition to current knowledge 
on the pharmacogenetics of moderate-to-severe plaque psoriasis. This type of studies 
could help optimizing the effectiveness of psoriasis therapy, thereby increasing its cost-
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effectiveness and decreasing the risk of adverse events. Nevertheless, further studies 
would be necessary to implement these genetic tests to the clinical practice.  
 
5. Conclusions 
 
 
A few studies have been performed about the pharmacogenetics of adalimumab and 
infliximab treatment in psoriatic patients. Polymorphisms in IVL, IL-12B, NFKBIA, 
ZNF816A and SLC9A8 genes were associated with PASI75 at 3 months of adalimumab 
or infliximab treatment. Moreover, a SNP located in TNFR1B was associated with 
PASI75 at 6 months of treatment with adalimumab or infliximab.        
                                                                                                                                                                                                                                                              
6. Executive summary 
 
 
Background  
  Adalimumab and infliximab are antibodies against TNFα. Although they are effective 
drugs to treat moderate-to-severe psoriasis, not all patients get an adequate response 
and some patients may develop adverse effects. A few studies have evaluated the 
influence of pharmacogenetic in patients with psoriasis treated with anti-TNF agents 
(Table 1).  
Patients & methods  
  We evaluated the association between 124 polymorphisms and the response to 
adalimumab or infliximab (PASI75) at 3 and 6 months of treatment in 95 and 90 
patients respectively. We tested different logistic regression models and adjusted our 
results using multivariate analysis. 
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Results & conclusion 
 We found an association between SNPs in IL-12B, IVL, SLC9A8, NFKBIA, 
ZNF816A genes and adalimumab or infliximab response at 3 months of treatment.  
 We found that a SNP in TNFR1B could predict adalimumab or infliximab response at 
6 months of treatment. 
   Further studies would be necessary to confirm the role of these genes in the response 
to adalimumab and infliximab. 
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 Table 1. Phenotypic characteristics of psoriatic patients treated with adalimumab and infliximab. 
 
 
 
Abbreviations: Data are shown as mean and standard deviation or number (%); PsA: psoriatic arthritis; 
PASI: psoriasis area severity index; 
1
early-onset psoriasis (<40 years); 
2 
late-onset (>40 years); Statistical 
differences were performed between responders and non-responder patients. T-test and χ2 were performed 
for continuous and categorical variables respectively.  
  
 
Patients 
(N=95) 
Responders 
(N=67) 
Non-responders 
(N=28) 
Statistical 
significance 
Age at onset of psoriasis (years) 27.8± 12.8 27.5 ± 13.1 28.7 ± 12.2 p=0.400 
Men (%) 60 (63.2) 42 (62.7) 18 (64.3) p=0.833 
Weight (Kg) 76.4 ± 13.3 75.5 ± 13.3 78.7± 13.1 p=0.972 
Adalimumab (%) 63 (66.3) 43 (64.2) 20 (71.4) 
p=0.495 
Infliximab (%) 32 (33.7) 24 (35.8) 8 (28.6) 
Psoriasis Type I (%)¹ 79 (83.2) 55 (82.1) 24 (85.7) 
p=0.667 
Psoriasis Type II (%)² 16 (16.8) 12 (17.9) 4 (14.3) 
Patients with PsA (%) 19 (20.0) 14 (20.9) 5 (17.9) p=0.736 
Age at first biological agent 
(years) 
42.8 ± 14.2 42.4 ± 14.8 43.7± 12.8              p=0.513 
Baseline PASI 22.1 ± 11.6 22.6 ± 11.9 20.8 ± 11.0 p=0.529 
Clinical response at 3 months of treatment 
PASI at 3 months 3.9 ± 5.6 1.2 ± 1.7 10.3 ± 6.3   p=0.000 
PASI75 (%) 67 (70.5) 67 (100) 0 (0)  
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Table 2. Summary of the results of univariate and multivariate logistic regression analyses for PASI75 at 
3 months of treatment (N=95). Only polymorphisms significant for the univariate analysis (p<0.05) are 
shown and were included in the multivariate analysis. 
 
 UNIVARIATE 
ANALYSIS 
MULTIVARIATE 
ANALYSIS 
 
SNP Gene Model Risk Genotype 
(% Responders /% 
Non-responders) 
OR (95% CI) p 
value 
OR (95% CI) p 
value 
rs1800896 IL-10 A AG-GG (64.2-81.5) 2.19 (1.07-4.47) 0.028 2.46 (0.53-11.37) 0.249 
rs2243188 IL-19 R AA (10.4-0.0) 0.00 (0.00-ND) 0.024 0.00 (0.00-ND) 0.999 
rs6661932 IVL A CT-TT (65.7-85.2) 2.15 (1.09-4.21) 0.022 13.08 (1.11-154.37) 0.041 
rs821421 PGLYRP3 D AC-AA (23.9-53.6) 3.68 (1.45-9.33) 0.006 3.17 (0.33-30.86) 0.321 
rs1500941 SPRR2F D AG-GG (74.6-53.6) 0.39 (0.16-0.99) 0.048 0.41 (0.02-8.94) 0.567 
rs191190 TNFR1 C CT (46.3-75.0) 2.71 (0.88-8.35) 0.024 0.02 (0.00-4.31) 0.148 
rs7744 MyD88 A AG-GG (16.4-35.7) 2.49 (1.07-5.82) 0.003 0.72 (0.06-8.47) 0.796 
rs2546890 IL-12B A AG-AA (80.6-60.7) 0.42 (0.20-0.87) 0.015 0.12 (0.01-0.95) 0.044 
rs2431697 PTTG1 R CC (13.4-33.3) 3.22 (1.11-9.34) 0.032 10.85 (0.69-171.36)  0.090 
rs1050152 SLC22A4 A CT-TT (74.6-57.1) 0.51(0.28-0.95) 0.028 0.47 (0.09-2.45) 0.366 
rs6908425 CDKAL1 A CT-TT (34.3-17.9) 0.41 (0.15-1.09) 0.050 0.64 (0.00-1.12) 0.060 
rs610604 TNFAIP3 R CC (19.4-3.6) 0.15 (0.02-1.24) 0.027 0.02 (0.00-5.97) 0.173 
rs774359 C9orf72 R CC (9.1-0.0) 0.00 (0.00-ND) 0.038 0.00 (0.00-ND) 0.999 
rs2145623 NFKBIA A CG-GG (50.0-67.9) 1.98 (1.04-3.75) 0.034 6.64 (1.13-39.23) 0.037 
rs4775912 USP8-
TNFAIP8L3 
A CT-CC (34.3-14.3) 0.33 (0.11-0.99) 0.027 0.09 (0.00-1.45) 0.089 
rs4792847 MAP3K14 D AG-AA (57.6-78.6) 2.70 (0.97-7.54) 0.047 5.09 (0.35-73.35) 0.232 
rs4788850 NAT9 D CG (11.9-0.0) 0.00 (0.00-ND) 0.015 0.00 (0.00-ND) 0.999 
rs9304742 ZNF816A D CT-CC (70.2-42.9) 0.32 (0.13-0.80) 0.013 0.01 (0.00-0.30) 0.008 
rs645544 SLC9A8 R GG (6.0-21.4) 4.30 (1.11-16.65) 0.033 73.54 (1.33-4,075.18) 0.036 
 
Abbreviations: IL-10: Interleukin 10; IL-19: Interleukin 19; IVL: Involucrin; PGLYRP3; Peptidoglycan 
Recognition Protein 3; SPRR2F: Small Proline Rich Protein 2F; TNFR1: Tumor Necrosis Factor 
Receptor 1; MyD88: Myeloid Differentiation Primary Response 88; IL12B: Interleukin 12B; PTTG1: 
Pituitary Tumor-Transforming 1; SLC22A4: Soluble Carrier Family 22 member 4; CDKAL1: CDK5 
Regulatory Subunit Associated Protein 1 Like 1; TNFAIP3: TNF Alpha Induced Protein 3; C9orf72: 
Chromosome 9 open reading frame 72; NFKBIA: NFκB Inhibitor Alpha; USP8-TNFAIP8L3: Ubiquitin 
Specific Peptidase 8 - TNFα Alpha Induced Protein 8 Like 3; MAP3K14: Mitogen-Activated Protein 
Kinase Kinase Kinase 14; NAT9: N-acetyltransferase 9; ZNF816A: Zinc Finger Protein 816; SLC9A8: 
Soluble Carrier Family 9 member A8; SNP: Single Nucleotide Polymorphism; OR: Odds Ratio of non-
response; CI: Confidence Interval; C: Codominant; D: Dominant; A: Additive; R: Recessive; ND: No 
Data. Bold characters emphasize significant results for multivariate analysis.  
22 
 
 
Table 3. Results of univariate and multivariate logistic regression analyses for PASI75 at 6 months of 
treatment (N=90). Only polymorphisms significant for the univariate analysis (p<0.05) are shown and 
were included in the multivariate analysis. 
 
 UNIVARIATE ANALYSIS MULTIVARIATE 
ANALYSIS 
SNP Gene Mod
el 
Risk Genotype 
(% Responders/ 
% Non-responders) 
OR (95% CI) p 
 value 
OR (95% CI) p 
value 
rs1800896 IL-10 A AC-AA(49.3- 27.8) 0.39 (0.14-1.08) 0.048 0.69 (0.26-1.85) 0.457 
rs1500941 SPRR2F D AG-GG (75.0-50.0) 0.33 (0.11-0.97) 0.045 0.43 (0.12-1.54) 0.194 
rs1061622 TNFR1B D GT-GG (34.7-66.7) 3.76 (1.26-11.22) 0.014 2.01 (0.56-7.21) 0.286 
rs1061624 TNFR1B A AG-GG (73.5-93.3) 2.94 (1.15-7.53) 0.018 0.32 (0.12-0.86) 0.025 
rs397211 IL-1RN R CC (15.5-0.0) 0.00 (0.00-ND) 0.021 2.04 (0.36-11.5) 0.419 
rs96844 MAP3K1 D CT-CC (52.8-16.7) 0.18 (0.05-0.67) 0.004 0.40 (0.11-1.37) 0.143 
rs2431697 PTTG1 A CT-CC (63.4-83.3) 2.53 (1.15-5.54) 0.016 2.00 (0.85-4.74) 0.115 
rs13437088 HLA-B/MICA R TT (13.9-0) 0.00 (0.00-ND) 0.029 0.92 (0.13-6.71) 0.930 
rs2395029 HPC5 D GT (12.5-0) 0.00 (0.00-ND) 0.039 0.50 (0.03-8.34) 0.630 
rs6311 5-HTR2A D CC -CT (67.6-93.8) 7.19  (0.89-57.76) 0.018 0.62 (0.16-2.38) 0.485 
rs12459358 PSORS6 D CT-TT (64.8-33.3) 0.27 (0.09-0.81) 0.016 1.52 (0.45-5.16) 0.503 
 
Abbreviations: IL-10: Interleukin 10; SPRR2F: Small Proline Rich Protein 2F; TNFR1B: Tumor 
Necrosis Factor Receptor 1B; IL-1RN: Interleukin 1 Receptor Antagonist; MAP3K1: Mitogen-Activated 
Protein Kinase Kinase Kinase 1; PTTG1: Pituitary Tumor-Transforming 1; HLA-B/MICA: Human 
Leukocyte Antigen B/Mayor Histocompatibility Complex Class I Polypeptide-Related Sequence A; HLA-
B/MICA: HPC5: HLA Complex P5; 5-HTR2A: 5 Hydroxytryptamine Receptors 2A; PSOR6: Psoriasis 6; 
SNP: Single Nucleotide Polymorphism; OR: Odds Ratio of non-response; CI: Confidence Interval; D: 
Dominant; A: Additive; R: Recessive; ND: No Data. Bold characters represent significant results. 
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Table 4. SNPs associated with response to biological therapies in psoriasis patients in previous studies 
and correlation with the present study. Only significant results p<0.05 appear in this table. 
 
Gene SNP RG N Drugs Period 
Response 
Criteria 
Reference C 
CTNNA2 rs11126740 AA 144 Anti-TNF 3 PASI75 Prieto-Pérez et al. [24] NA 
FCGR2A rs1801274 T 144 Anti-TNF 6 PASI75 Prieto-Pérez et al. [24] CU 
HLA-C rs12191877 C 144 Anti-TNF 3 PASI75 Prieto-Pérez et al. [24] NC 
HTR2A rs6311 T 144 Anti-TNF 6 PASI75 Prieto-Pérez et al. [24] CU 
IL-12B rs2546890 A 144 Anti-TNF 3&6&12 PASI75 Prieto-Pérez et al. [24] C 
IL-17A rs4819554 AA 205 Anti-TNF 3 PASI75 Batalla et al. [27] NA 
IL-17F 
rs763780 
 
TT 
35/ 
62 
IFX/ 
ADA 
3&6/ 
6 
PASI75 
 
Prieto-Pérez et al. [23] NC 
IL-23R rs11209026 GG 33 IFX 6 PASI90 Gallo et al. [28] NC 
MAP3K1 rs96844 T 144 Anti-TNF 3&6 
PASI75 
 
Prieto-Pérez et al. [24] CU 
TNFα (-238) 
 
rs361525 
 
G 
109/27 
 
270 
57/ 
270/ 
80 
 
Anti-TNF/IFX 
 
 
Anti-TNF 
6 
 
3/ 
 
2 
PASI75/ 
%ImPASI/ 
 
 
PASI75 
Gallo et al. [28]/ 
 
Murdaca et al. [61]/ 
Song et al. [39]/ 
Vasilopoulos et al.[32] 
 
 
NA 
 
TNFα (-308) rs1800629 G 270 Anti-TNF  PASI75 Song et al.[39] NA 
TNFα (-857) 
 
rs1799724 
 
CC 
 
109/   27/ 
 
80/ 
270 
Anti-TNF/ 
IFX 
 
Anti-TNF 
 
6 
%ImPASI / 
PASI50&PASI7
5 
 
PASI75 
 
Gallo et al. [28]/ 
 
Vasilopoulos et al.[32]/ 
 
Song et al. [39] 
NA 
 
TNFα (-1031) rs1799964 TT 109/27 
Anti-TNF / 
IFX 
3&6 
PASI75/ PASI50 
& PASI75& 
PASI90 
Gallo et al. [28] NA 
TNFRSF1B rs1061622 TT 80/ 90 Anti-TNF 6 
PASI75 / 
PASI50 
Vasilopoulos et al. 
[32]/González-Lara et al. 
[57] 
CU 
TNFAIP3 
 
rs2230926 
/rs610604 
A 250 ADA 6 PASI75 Masouri et al. [42] 
CU 
 
rs2230926 
/rs610604 
T 55 Anti-TNF 
 
PASI50 Chen et al. [40] 
rs2230926 
/rs610604 
GG 433/51 Anti-TNF 3/ 6 
PASI50 
 
Talamonti et al. [62]/ 
Tejasvi et al. [37] 
rs2230926/ 
rs610604 
TG 433 Anti-TNF 6 PASI50 Tejasvi et al. [37] 
rs2230926/ 
rs610604 
TG 632 Anti-TNF 6 PASI50 Tejasvi et al. [37] 
rs2230926 TG 51 Anti-TNF 3 PASI75 Talamonti et al.[62] 
PDE3A-
SLCO1C1 
 
rs379471 G 103 Anti-TNF 3 %ImPASI Julià et al. [30] 
NA 
 
rs1048554 C 250 Anti-TNF 6 PASI75 Masouri et al. [35] 
rs9260313 TT 250 ADA 6 PASI75 Masouri et al. [35] 
PGLYRP4-24 rs2916205 AA 144 Anti-TNF 3 PASI75 Prieto-Pérez et al. [24] NA 
TRAF3IP2 rs13190932 GG 250 IFX 6 PASI75 Masouri et al. [35] NA 
ZNF816A rs9304742 T 144 Anti-TNF 3 PASI75 Prieto-Pérez et al. [24] NC 
 
Abbreviations: RG: Allele or genotype of response. N: number of patients; C: Confirmation of the genetic 
biomarkers in the present study; NA: not analyzed; NC: not confirmed in our study population; CU: 
Confirmed only in the univariate analysis; PASI: Psoriasis Area and Severity Index; PASI50: 50% of 
improvement respect basal PASI; PASI75: 75% of improvement respect basal PASI; PASI90: 90% of 
improvement respect basal PASI; ImPASI: Improvement of PASI; Anti- TNF: Anti- Tumor Necrosis 
Factor; ADA: Adalimumab; IFX: Infliximab. 
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Supplementary Table 1. Information of the 124 SNPs studied in the present study.  
 
Nº SNP CHROMOSOME REGION GENE MINOR 
ALLELE 
AMINOACID 
CHANGE 
1 rs699 1 Coding AGT C Pro>Leu 
2 rs928655 
1 Intronic GBP6 G No 
3 rs1800896 1 Intergenic IL10 G No 
4 rs1800872 
1 Intergenic IL10 G No 
5 rs2243188 1 Intronic IL19 A No 
6 rs2243158 
1 Intronic IL19 C No 
7 rs11209026 
1 Coding IL23R A Lys>Glu 
8 rs4649203 1 Intergenic IL28RA G No 
9 rs6661932 
1 Intergenic IVL T No 
10 rs6701216 1 Intronic LCE T No 
11 rs1886734 
1 Intronic LCE A No 
12 rs4112788 1 Intergenic LCE T No 
13 rs983332 1 Intergenic LMO4 A No 
14 rs10494292 
1 Intergenic LELP1 G No 
15 rs6684865 1 Intronic 
MMEL-
TNFRSF14 
A No 
16 rs1801133 1 Coding MTHFR T Ala>Val 
17 rs10754555 
1 Intronic NLRP3 G No 
18 rs2240340 1 Intronic PADI4 A No 
19 rs821421 1 Intergenic 
PGLYRP3-
19 
A No 
20 rs2206593 1 UTR PTGS2 A No 
21 rs2476601 
1 Coding PTPN22 A Arg>Trp 
22 rs10919563 1 Intronic PTPRC A No 
23 rs2485558 1 Intronic RYR2 G No 
24 rs1500941 
1 Intergenic SPRR2F G No 
25 rs191190 1 Intronic TNFR1 C No 
26 rs1061622 
1 Coding TNFR1B G Gly>Trp 
27 rs1061624 1 UTR TNFR1B A No 
28 rs3087243 2 Intergenic CTLA4 G No 
29 rs11126740 
2 Intronic CTNNA2 A No 
30 rs842636 2 Intergenic LINC01185 A No 
31 rs2164807 2 Intergenic 
GNLY-
ATOH8 
G No 
32 rs17716942 
2 Intronic IFIH1 C No 
33 rs17561 2 Coding IL1A T Val>Leu 
34 rs397211 2 Intergenic IL1RN C No 
35 rs13393173 
2 Intronic LASS6 A No 
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Nº SNP CHROMOSOME REGION GENE MINOR 
ALLELE 
AMINOACID 
CHANGE 
36 rs7574865 
2 Intronic STAT4 T No 
37 rs7744 3 UTR MyD88 G No 
38 rs1801282 
3 Coding PPAR-γ G Pro>Ala 
39 rs658971 3 Intronic SLC12A8 A No 
40 rs651630 3 Intronic SLC12A8 T No 
41 rs437943 
4 Intergenic EPS15 G No 
42 rs6822844 4 Intergenic IL21 T No 
43 rs11096957 
4 Coding TLR10/1/6 C Tyr>Ser 
44 rs2289318 4 Intronic TLR2 G No 
45 rs1232027 
5 Intergenic DHFR A No 
46 rs3213094 5 Intronic IL12B A No 
47 rs2546890 
5 Intergenic IL12B A No 
48 rs1800925 
5 Intergenic IL13 T No 
49 rs848 5 UTR IL13 T No 
50 rs96844 
5 Intergenic MAP3K1 C No 
51 rs2431697 5 Intergenic PTTG1 C No 
52 rs1050152 5 Coding SLC22A4 T No 
53 rs17728338 
5 Intergenic TNIP1 A No 
54 rs2073048 6 Intronic C6orf10 T No 
55 rs879882 
6 Intergenic HLA-C T No 
56 rs13437088 6 Intergenic 
HLA-
B/MICA 
T No 
57 rs12191877 6 Intergenic HLA-C T No 
58 rs2395029 
6 Coding HPC5 G Gly>Trp 
59 rs2275913 
6 Intronic IL17A C His>Arg 
60 rs10484879 6 Intronic IL17A A No 
61 rs763780 
6 Intergenic IL17F T No 
62 rs1342642 6 Coding IL20RA T Thr>Ile 
63 rs1167846 6 Intronic IL20RA T No 
64 rs2010963 
6 UTR VEGF C No 
65 rs241447 6 Coding TAP2 G Asp>Gly 
66 rs17587 
6 Coding LMP A Thr>Ala 
67 rs6920220 6 Intergenic TNFAIP3 A No 
68 rs610604 
6 Intronic TNFAIP3 C No 
69 rs909253 6 Intronic LTA C No 
70 rs240993 6 Intronic TRAF3IP2 T No 
71 rs33980500 
6 Coding TRAF3IP2 T Gln>Stop 
72 rs13210247 6 Intronic TRAF3IP2 G No 
73 rs6908425 
6 Intronic CDKAL1 T No 
74 rs916514 7 Intronic DPP6 C No 
75 rs1799983 7 Coding eNOS T Ser>Ile 
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76 rs1800795 
7 Intergenic IL6 C No 
77 rs854548 7 Intergenic PON1 A No 
78 rs10088247 
8 Intronic CSMD1 C No 
79 rs11986055 8 Intronic IKBKB C No 
80 rs1799929 8 Coding NAT2 T No 
81 rs774359 
9 UTR C9orf72 C No 
82 rs1076160 9 Intronic TSC1 A No 
83 rs4962153 
9 Intronic TTP A No 
84 rs11591741 10 Intronic CHUK C No 
85 rs187238 
11 Intergenic IL18 C No 
86 rs2430561 12 Intronic IFN-γ A No 
87 rs11541076 
12 UTR IRAK3 A No 
88 rs12580100 
12 Intergenic RPS26 G No 
89 rs767455 12 Coding TNFR1 C No 
90 rs4516035 
12 Intergenic VDR C No 
91 rs6311 13 Intergenic 5-HTR2A T No 
92 rs3812888 13 Intronic COG6 C No 
93 rs7993214 
13 Intronic COG6 T No 
94 rs3751385 13 UTR GJB2 T No 
95 rs2282276 
14 Intronic CLMN C No 
96 rs2145623 14 Intergenic NFKBIA C No 
97 rs2254441 
15 Intronic PSTP1P1 A No 
98 rs4775912 15 Intronic 
USP8-
TNFAIP8L3 
C No 
99 rs4785452 
16 Intergenic CYLD T No 
100 rs10782001 16 Intronic FBXL19 G No 
101 rs8056611 
16 Intergenic CYLD A No 
102 rs1975974 17 Intergenic C17orf51 G No 
103 rs1634517 17 Intronic CCL4L A No 
104 rs4792847 
17 Intronic MAP3K14 A No 
105 rs1024611 17 Intergenic MCP1 C No 
106 rs4788850 
17 Coding NAT9 G Ala>Gly 
107 rs4795067 17 Intronic NOS2 G No 
108 rs763361 
18 Coding CD226 T Pro>Leu 
109 rs514315 18 Intergenic SERPINB8 C No 
110 rs3136645 19 Coding NFKBIB C No 
111 rs9403 
19 UTR NFKBIB C No 
112 rs12459358 19 Intergenic PSORS6 T No 
113 rs12983316 
19 Intronic SMARCA4 G No 
114 rs12720356 19 Coding TYK2 G Gly>Val 
115 rs9304742 19 Intergenic ZNF816A C No 
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116 rs597980 
20 Intronic ADAM33 T No 
117 rs2787094 20 UTR ADAM33 C No 
118 rs6138150 
20 Intergenic CST5 C No 
119 rs6071980 20 Intergenic MAFB C No 
120 rs2769982 20 Coding RNF114 C No 
121 rs1008953 
20 Intergenic SDC4 A No 
122 rs645544 20 Intronic SLC9A8 G No 
123 rs3761548 
X Intronic FOXP3 C No 
124 rs3027898 X Intergenic IRAK1 C No 
 
